Humanized Anti-CD138 ADC Composition for Low-Immunogenicity Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) targeting CD138-expressing cancer cells face challenges such as immunogenicity, instability, and aggregation, limiting their effectiveness and safety as anti-tumor agents.
Innovation Solution
Development of a humanized IgG1 antibody with specific binding capability to CD138, combined with various linkers and payloads, resulting in an ADC that is stable, reduces immunogenicity, and minimizes aggregation, ensuring high anti-tumor efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a chimeric antibody is used as the antibody component of the ADC, then the ADC can bind to CD138 and exert cytotoxic activity, but the immunogenicity risk increases
Solution Approach 1:
The patent applies parameter changes by transitioning from a chimeric antibody to a humanized antibody with modified amino acid sequences. This changes the immunogenicity parameter while maintaining the binding capability to CD138, thereby reducing immunogenicity risk while preserving therapeutic effectiveness.
Solution Approach 2:
The patent uses a composite approach by combining the variable region of a non-human antibody (for CD138 binding) with the constant region of a human IgG1 antibody. This creates a humanized antibody that retains antigen-binding capability while reducing immunogenicity through human sequence elements.
2Reliability
If a small difference in antibody sequences is made, then the binding capability may change, but physical properties change causing antibody aggregation and lowered stability
Solution Approach 1:
The patent carefully optimizes amino acid sequences through parameter changes, specifically engineering the humanized antibody to have exactly 95-98% sequence identity to reference sequences. This controlled parameter change maintains binding capability while improving physical stability and reducing aggregation.
Solution Approach 2:
The patent employs feedback mechanisms by systematically evaluating multiple antibody variants with different sequence identities. Through iterative testing and optimization, the patent identifies the optimal sequence identity range (95-98%) that balances binding capability with physical stability, preventing aggregation.
3Reliability
If various linkers and payloads are combined with antibodies, then the anti-tumor activity can be enhanced, but the development complexity increases requiring screening for every antibody sequence
Solution Approach 1:
The patent establishes a universal platform by creating a humanized anti-CD138 antibody that can be paired with various linkers and payloads (MMAE, DM1, DM4). This multi-functional antibody design allows a single antibody sequence to work effectively with multiple drug conjugates, reducing the need for extensive screening of different antibody sequences for each payload combination.
Data Source
Figure 1A~1B
Figure 2-1
Figure 2-2
AI summary
This invention provides an antibody-drug conjugate (ADC) that binds specifically to CD138 and exerts excellent anti-tumor effects thereon. Such antibody-drug conjugate (ADC) comprises the anti-CD138 antibody comprising a particular amino acid sequence and monomethyl auristatin E bound thereto via a linker.